Calendario›SNY›Meningococcal Polysaccharide…

Meningococcal Polysaccharide…

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Ensayo de Sanofi en Meningitis · Meningococcal Infection (del registro, en inglés).

Fase

Fase 2

Estado

Completado

Participantes

145

previstos

Centros

8

Fin del objetivo primario

feb 2007

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en dic 2005.

Qué mide

Participants With Serum Bactericidal Activity of ≥ 1:8 for Each Menactra® Vaccine Serogroups Pre-vaccination and 28 Days Post-booster or Post-primary Dose Vaccination. (28 days post-vaccination (5 years after Menactra® or Menomune® vaccination)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 15 to 23 years (not yet 24 years) who had been vaccinated five years previously in Study MTA02 and did not participate in Study MTA19 (NCT 00777790). In addition, the kinetics of the antibody response will be evaluated in a subset of these participants who will receive a booster dose of Menactra® vaccine. This will be compared to aged matched control subjects who have not been previously vaccinated with a meningococcal vaccine or had documented meningitis disease who will also receive a dose of Menactra® vaccine.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00269477), actualizada en abr 2016.